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Table 1.- Absolute risk of arterial and venous 
occlusive events in patients with CML.
 Overall, 4.47% (99/2,217) of patients developed 
arterial occlusive events with new generation 
BCR-ABL TKIs compared with 0.80% (15/1,884) 
with imatinib (REM ORPETO: 3.46; 95%CI: 2.35 to 
5.10). 
 Venous occlusive events occurred in only 0.59% 
(13/2,217) of patients treated with new 
generation TKIs and in 0.16% (3/1,884) of 
imatinib-treated patients. 
Figure 1.- PRISMA (Preferred Reporting Items for 
Systematic review and Meta-Analysis) flow diagram of 
study selection
 Twelve studies fulfilled the established criteria and 
were included in the meta-analysis. 
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BACKGROUND
High rate of arterial and venous occlusive events were reported 
with ponatinib during clinical development1 and serious cases of 
arterial occlusive disease were also reported with nilotinib.2 This 
led to the evaluation of the vascular safety profile of new 
generation BCR-ABL TKIs through a meta-analysis that confirmed 
the increased risk of vascular occlusive events with ponatinib and 
nilotinib compared with imatinib in chronic myeloid leukemia 
(CML). The risk was also with dasatinib.3 However, distinction 
between arterial of venous events was not assessed.
OBJECTIVES
 To determine the risk of arterial and venous occlusive events in 
patients with Ph+ CML treated with new generation BCR-ABL 
TKIs in randomized clinical trials.
 Stratifications by treatment are performed to provide product 
specific risk assessment.
Limitations
 Lack of time-to-event analyses
 Inconsistent report of cardiovascular events in the 
literature. 
However, the use of a clinical trial register aimed to 
decrease this heterogeneity, and funnel plots 
demonstrate no evidences of publication bias. The I2
statistic specifies no heterogeneity among studies 
(data not shown).
Treatments
Venous occlusive events Arterial occlusive events
New 
generation TKIs
Imatinib
New 
generation TKIs
Imatinib
Nilotinib 4/886 (0.45) 0/608 (0.00) 69/886 (7.79) 7/608 (1.15)
Dasatinib 8/929 (0.86) 3/873 (0.34) 16/929 (1.72) 4/873 (0.46)
Bosutinib 0/248 (0.00) 0/251 (0.00) 3/248 (1.21) 1/251 (0.40)
Ponatinib 1/154 (0.65) 0/152 (0.00) 11/154 (7.14) 3/152 (1.97)
Overall 13/2217 (0.59) 3/1884 (0.16) 99/2217 (4.47) 15/1884 (0.80)
RESULTS
Figure 2.- Forest plots of arterial and venous occlusive 
events in patients with Ph+ CML treated with new 
generation TKIs versus imatinib.
 Overall, new generation TKIs increase the rate of venous 
(FEM ORPETO: 2.85; 95%CI: 1.04 to 7.78) and arterial (REM 
ORPETO: 3.462; 95%CI: 2.35 to 5.10) occlusive events.
 Ponatinib, nilotinib and dasatinib are associated with 
higher risk of arterial occlusive events than imatinib. 
 No significant difference was found with bosutinib but a 
trend indicate an increased risk of arterial occlusive 
events.
 Stratification by treatment for venous analysis 
demonstrates nonsignificant results due to the low power 
of the analysis.
DISCLOSURES REFERENCES
METHODS
Literature search
 Screening of scientific articles (PubMed, Scopus, Cochrane 
library), congress abstracts (ASH, ASCO, ESMO) and clinical trial 
register (www.clinicaltrials.gov).
 Selection of all randomized clinical trials comparing new 
generation TKIs versus imatinib in patients with Ph+ CML.
Data collection
 Study and population characteristics
 Arterial occlusive events
 Venous occlusive events
Statistical analysis
 Random- (REM) and fixed-effect models (FEM) have been used 
to analyze the risk of arterial occlusive events and venous 
occlusive events respectively.
 Effect size measure: Odds ratio computing using Peto method.
 Heterogeneity assessment: Cochran’s Q statistic and I2 value.
 One-way sensitivity analysis was performed to assess the 
robustness.
CONCLUSIONS
 New generation TKIs increased risk of arterial and 
venous occlusive events compared with imatinib.
 The increased risk of vascular occlusive events 
associated with new generation TKIs is mainly driven by 
thrombotic events occurring at the arterial side.
 Additional investigations are required to assess the 
underlying pathophysiological mechanisms.
 Appropriate risk minimization measures should be 
taken/implemented with nilotinib, dasatinib and 
ponatinib.
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Scopus
187 articles
(148 articles)
The Cochrane 
database
128 articles
(95 articles)
Abstracts 
from congress
397 abstracts
(238 abstracts)
clinicaltrials.gov
489 trials
(270 trials)
Total abstracts for 
screening
N=770
(N=527)
First screening
N=407
(N=249)
Record excluded
N=348
Articles and 
abstracts eligible
N=59
(N=49)
23 articles (19)
36 abstracts (30) 
included for 
eligibility
18 articles and 35 abstracts 
excluded:
4 not in leukemic patients
22 updated data published
1 review
8 sub-analysis (5)
1 trial description
17 without pertinent data (8)
12 studies included for 
qualitative synthesis: 
(10)
•1 abstract (3)
•5 articles (6)
•6 clinicaltrials.gov (1) 
Trials meeting 
inclusion/exclusion 
criteria
N=21
(N=19)
9 studies excluded
 6 without results
 2 without vascular 
occlusive events
 1 without analysis
PubMed
58 articles
(46 articles)
12 studies included for 
quantitative synthesis: 
(10)
•1 abstract (3)
•5 articles (6)
•6 clinicaltrials.gov (1) 
Arterial occlusive events
Venous occlusive events
François Mullier reports personal fees from Boehringer
Ingelheim, Bayer Healthcare and Bristol-Myers Squibb-Pfizer 
outside the submitted work. Carlos Graux reports personal 
fees from Novartis, Celgene, and Amgen, outside the 
submitted work. The other authors have no conflict of interest 
to disclose.
H. Haguet: helene.haguet@gmail.com
J. Douxfils: jonathan.douxfils@unamur.be
J-M Dogné: jean-michel.dogne@unamur.be
CONTACT INFORMATION
E1096
